W0101 - Pierre Fabre Medicament

Drug Profile

W0101 - Pierre Fabre Medicament

Alternative Names: W-0101

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Oct 2017 Preclinical trials in Cancer in France (Parenteral)
  • 20 Oct 2017 Pierre Fabre plans a phase I/II trial in Solid tumours (late-stage disease, Metastatic disease) in France and Spain in November 2017 (NCT03316638)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top